Beta Bionics (NASDAQ:BBNX) Research Coverage Started at Stifel Nicolaus

Stifel Nicolaus assumed coverage on shares of Beta Bionics (NASDAQ:BBNX) in a report released on Monday, Marketbeat.com reports. The firm issued a buy rating and a $25.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Piper Sandler initiated coverage on shares of Beta Bionics in a report on Monday. They set an “overweight” rating and a $26.00 target price for the company. Leerink Partners assumed coverage on Beta Bionics in a research note on Monday. They set an “outperform” rating and a $28.00 price objective for the company. Baird R W raised Beta Bionics to a “hold” rating in a report on Thursday, February 20th. LADENBURG THALM/SH SH started coverage on Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 price target for the company. Finally, Robert W. Baird initiated coverage on shares of Beta Bionics in a research note on Thursday, February 20th. They issued a “neutral” rating and a $20.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Beta Bionics currently has an average rating of “Moderate Buy” and an average target price of $24.83.

Beta Bionics Stock Up 4.3 %

NASDAQ:BBNX opened at $19.99 on Monday. Beta Bionics has a 1-year low of $18.67 and a 1-year high of $24.50.

Insider Buying and Selling

In related news, insider Mike Mensinger acquired 33,350 shares of the firm’s stock in a transaction dated Friday, January 31st. The shares were purchased at an average price of $17.00 per share, with a total value of $566,950.00. Following the completion of the purchase, the insider now directly owns 59,019 shares of the company’s stock, valued at $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was purchased at an average price of $17.00 per share, with a total value of $17,000,000.00. Following the completion of the transaction, the insider now owns 3,901,599 shares of the company’s stock, valued at approximately $66,327,183. This trade represents a 34.46 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Beta Bionics

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.